New allergy shot under safety spotlight
NCT ID NCT07459556
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test the safety of a new biologic drug called stapokibart, given as a shot, in 400 adults with seasonal allergic rhinitis (SAR). Participants are already prescribed the drug by their doctor. The main goal is to track any side effects. This is an open-label study, meaning everyone knows they are getting the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stapokibart (a biologic drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a safe treatment option for seasonal allergic rhinitis.
What could go wrong
This is an early safety study, not designed to prove the drug works. Side effects or lack of effectiveness may limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital, CMU
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••